Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation

Enrico G Ferro^{1

2

3}, Dhruv S Kazi^{1

2

3}, Peter J Zimetbaum^{1

2

3

4}

Affiliations

¹ Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
² Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Harvard Thorndike Arrhythmia Service, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Editorial

Enrico G Ferro et al. JAMA. 2021.

. 2021 Dec 21;326(23):2372-2374.

doi: 10.1001/jama.2021.21305.

Enrico G Ferro^{1

2

3}, Dhruv S Kazi^{1

2

3}, Peter J Zimetbaum^{1

2

3

4}

¹ Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
² Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Harvard Thorndike Arrhythmia Service, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

No abstract available

Comment on

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. Ray WA, et al. JAMA. 2021 Dec 21;326(23):2395-2404. doi: 10.1001/jama.2021.21222. JAMA. 2021. PMID: 34932078 Free PMC article.